STUNNING LONG-TERM SURVIVAL OF FORMER END-STAGE CANCER PATIENTS – WHILE FDA STALLS BROADER APPROVALS $IBRX I've been following ImmunityBio, Inc. for a while now, and every time I dive deeper, I'm blown away by the real-world impact of their BioShield platform—anchored by ANKTIVA.

If you are following me because of investing in $IBRX , remember this... Any technical analysis of a stock under $5 for anything but day trading is bullshit - Grok it if you don’t believe me. If there is someone on here posting charts, levels, etc - they are likely pumping and

$IBRX LONG COVID The study plan for the Interrupt_LC trial (NCT07108036; Phase 2; COVID-4.018-LONG) to assess the safety and tolerability of Anktiva (N-803) in patients with Long Covid is now available online. clinicaltrials.gov/study/NCT07108…

Moderate alcohol consumption (just 1 drink a day) can double a woman's risk of breast cancer from 1 in 8 to 1 in 4 Even light drinking (<7 drinks per week) raises a woman's lifetime breast cancer risk from 1 in 8 to roughly 1 in 7 Alcohol directly damages DNA and accelerates

Sorry for the pause in Cancer Decoded. Have been busy reviewing amazing data in multiple different tumor types in patients receiving the Bioshield platform..from patients with brain tumors who failed current standards of care to rare forms of Lymphoma. News out this week.

👊🏼Bioshield Complete. 🚫 colon cancer 🚫 #cancer #coloncancer #chemo #capecitabine #bioshield #MAHA ImmunityBio, Inc. $IBRX

We announced early results from our QUILT-106 Phase I trial showing complete responses in the first two late-stage Non-Hodgkin Waldenström lymphoma patients treated with our CD19 CAR-NK cell therapy. Learn more: immunitybio.com/immunitybio-re…

COMPLETE RESPONSES WITH NK CELL THERAPY. The power of the Bioshield platform. A tumor agnostic chemo free paradigm change by treating the immune system. Lymphoma trial is open. Contact CSSIFM to enroll. Next news coming - glioblastoma.

The power of NK cells. After a single cycle of NK cells targeting the tumor the patient with a rare lymphoma (WM) -90 percent of bone marrow infiltrated ( left PET scan) achieved a COMPLETE RESPONSE ( right scan). Had failed all other therapy. The power of the BIOSHIELD platform.

Trial of Bioshield to explore treatment of Long Covid is open!! Please enquire via this form at cssifm.org and our team will respond to the many requests for Bioshield #anktiva #longcovid

Dr. Patrick Soon-Shiong & Gretchen’s Journey—A New Paradigm in Cancer Treatment 1/ When cancer strikes early, the goal is cure—not just management. Gretchen’s story isn’t just hope; it’s science in action. Dr. Soon-Shiong reveals how a triple-threat approach—educating T-cells,

Next randomized trial in preparation : patients with Glioblastoma ( brain tumor) who have failed all standards of care. Sadly the progression free survival in these patients is measured in a few months. Our goal is to change this with Anktiva and NK cell therapy. Trial coming

Bullish Scott Adams Dr. Pat Soon-Shiong Dr. Shiong, to me embodies the inscription from The Last Samurai—“I belong to the warrior in whom the old ways have joined the new.” His revolutionary approach integrates decades of clinical surgical, pharmaceutical and even a touch of astrophysics with cutting-edge

We've announced our new study, called COVID-4.019-Long, which further expands our clinical research efforts to assess ANKTIVA’s potential beyond cancer or cancer-related diseases. Learn more about the study and its potential impact: ir.immunitybio.com/news-releases/…

Who would have thought in 2025 that cancer treatment could mean living — not saying goodbye to your husband and children? Dr. Shiong did! Ask your doctor if they’ve ever seen a colon cancer patient, mid-chemo/radiation treatment, working out like her. For my mom, hope came just

Patient would like me to share this wonderful response to the Bioshield.. from not being able to speak clearly because of tumor to now singing his song in our clinic. What a blessing.

Post Bioshield Test Results! #cancersurveillance #cancer #coloncancer #chemo #bioshield $IBRX ImmunityBio, Inc. Colorectal Cancer Alliance

$IBRX is @fda waiting till most Glioblastoma patients are dead? Let us look, ANKTIVA is clear for safety and approved with 10+ years worth of safety data. Why wait on terminal disease such cancer especially Glioblastoma? Dr. Marty Makary needs to expedite the approval as soon as

Initial data shows 2 patients with near Complete Response & 100% disease control in first 5 patients. When the immune system is protected, CR in tumors difficult to treat in recurrent GBM is possible. GBM trial open at CSSIFM.org Data for lung cancer next #WCLC25